FOLR1 and neoplasm: Next, in the MIRASOL trial (NCT04209855), a phase 3 study, safety and efficacy of MIRV treatment (in 227 patients administered at dose of 6 mg/kg adjusted for ideal body weight) was compared to chemotherapy (in 226 patients administered with paclitaxel, pegylated liposomal doxorubicin [PLD], or topotecan) in PROC patients who had received prior 1 to 3 prior treatments (total 453 patients) and had high FRα tumor expression.